DTMTM SCS SUPERIOR PAIN RELIEF PROVEN1

A new therapy inspired by science and proven only on Intellis™ with Overdrive™ battery technology.

DTM™ SCS OVERVIEW

DTM™ (differential target multiplexed) spinal cord stimulation (SCS) is a proprietary waveform supported by pre-clinical research and clinical research now within an RCT.  DTM™ SCS is a novel spinal cord stimulation (SCS) waveform delivered via the Medtronic Intellis™ platform, to treat patients with chronic, intractable pain.

Medtronic is invested in building long-term evidence for DTM™ SCS.

 

pdf CLINICAL STUDY (.pdf)

See the primary and secondary outcomes of the 12 month RCT results

456KB

View the highlights

BEYOND THE NEURON

Decades of basic science research have expanded the understanding of the role of glial cells in the nervous system, which outnumber neurons 12:1 in the spinal cord.2-5

TOWARD A NEW THEORY

Preclinical research6-11 suggests the ability of DTM™ SCS to impact neuronal-glial cell interaction, expanding the understanding of a new SCS MoA. DTM™ waveform best modulates glial and neuronal gene expression back toward the non-pain state.

Image of the front of Medtronic Intellis with AdaptiveStim
glial cells animated

INSPIRED BY SCIENCE  

The DTM™ waveform is the first SCS therapy intentionally developed from preclinical science.7
  

 

PROVEN ONLY

ON THE INTELLIS™ PLATFORM

DTM™ SCS proved sustained superiority compared to conventional stimulation at 3 and 12 months12.

Learn more about the RCT

evolution of dtm™ scs

Detailed Brochure

pdf DTM™ SCS RCT (.pdf)

A new therapy inspired by science and proven only on Intellis™ with Overdrive™ battery technology.

501KB

Download the Study results here

HYPOTHESISED NOVEL MECHANISM

Glia are electrically responsive cells in the spinal cord and outnumber neurons by 12:1.5 Chronic pain occurs when neuro-glial interactions get out of sync. DTM™ SCS may impact the neuronal-glial interaction.2-4

PRECLINICAL WORK

DTM™ SCS has been studied in animal models, showing statistically significant reversal of pain behaviours compared to either low frequency or high frequency alone.8 In addition, preclinical studies investigating the genome of nerve-injured animals suggests that the DTM™ waveform has a greater impact in the neural-glial interaction than other frequencies alone.8-11



THE INTELLIS™ PLATFORM

The Intellis™ SCS platform combines the smallest available neurostimulator with a suite of cutting-edge technologies, outcomes, and services that redefine what clinicians and patients should expect from chronic pain management.

MRI GUIDELINES
And Resources

Understand the differences in MRI conditionality between Medtronic SureScan™ MRI and other various manufacturers. Download the MRI Comparison Chart.

Download Guidelines
SCS intellis Platform Family

OVERDRIVETM BATTERY TECHNOLOGY

Unrivalled battery chemistry performance.


Learn about OverdriveTM

THE EVOLVESM WORKFLOW

Standardised guidance to optimise patient therapy with HD and LD dosing options

Learn about the workflow

the FOCUSSM workflow

Peripheral Nerve Stimulation for Chronic Back Pain.

Learn about the workflow

REQUEST MORE

INFORMATION

CONTACT US
Image of a family having a meal with grandparents
*

Study completed on the Intellis (TM) device

MR Safety Triangle Under specific conditions and requires SureScan™ MRI implantable neurostimulator and leads. Refer to product labelling for full list of conditions.

See the device/therapy manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events, If using an MRI SureScanTM device, see the MRI SureScanTM technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.

1

Back pain relief at 3-months compared to conventional stimulation. Fishman M, Cordner H, Justiz R, et al. Randomized Controlled Clinical Trial to Study the Effects of DTM-SCS in Treating Intractable Chronic Low Back Pain: 3 Month Results. Presentation at NANS 2020, Las Vegas, Nevada. Study done with the Intellis™ device.  

2

Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2009 Jan;10(1):23-36.

3

Vallejo R, Tilley DM, Vogel L, Benyamin R. The role of glia and the immune system in the development and maintenance of neuropathic pain. Pain Pract. 2010 May-Jun;10(3):167-84.

4

De Leo JA, Tawfik VL, LaCroix-Fralish ML. The tetrapartite synapse: Path to CNS centralization and chronic pain. Pain. 2006; 122:17-21.

5

Ruiz-Sauri A., Orduña-Valls J.M., Blasco-Serra A. et al. Glia to neuron ratio in the posterior aspect of the human spinal cord at thoracic segments relevant to spinal cord stimulation. Journal of Anatomy, vol. 235, no. 5, 2019, pp. 997-1006.

6

Cedeno D.L., Cass C.L., Kelley C.A., et al. Pre-clinical Comparison of Differential-Target Multiplexed SCS with Low and High Rate SCS. Neuromodulation 2019 22:3 (E185-)

7

Cedeno D.L., Kelley C.A., Cass C.L., et al. Pre-clinical Comparison of Differential-Target Multiplexed SCS with Low and High Rate SCS. Presentation at ASRA 2018. San Antonio, Texas.

8

Vallejo R, Kelley CA, Gupta A, Smith WJ, Vallejo A, Cedeño DL. Modulation of neuroglial interactions using differential target multiplexed spinal cord stimulation in an animal model of neuropathic pain. Mol Pain. 2020 Jan-Dec;16:1744806920918057.  

9

Vallejo R, Smith W, Kelley C, et al. Neuron-glial inflammasome enhanced reversal by DTM-SCS relative to high rate and low rate SCS in a neuropathic pain model. American Society for Regional Anesthesiology and Pain Medicine (ASRA); November 14-17, 2019; New Orleans, LA. Abstract #480 

10

Vallejo R, Kelley C, Smith W, et al. Cell-specific targeting in neural tissue using Differential Target Multiplexed (DTM) SCS. American Society for Regional Anesthesiology and Pain Medicine (ASRA); November 14-17, 2019; New Orleans, LA. Abstract #513

11

Vallejo R, Tilley D, Kelley C, et al. Proteomics of Differential Target Multiplexed-SCS applied to an animal model of neuropathic pain. American Society for Regional Anesthesiology and Pain Medicine (ASRA); November 14-17, 2019; New Orleans, LA. Abstract #509  

12

Fishman M, Cordner H, et al. DTM™ SCS RCT 12-month data results. Presented at a Medtronic webinar, jointly supported by the North American Neuromodulation Society (NANS), World Institute of Pain (WIP), and the American Society for Pain and Neuroscience (ASPN). October 19, 2020. Webinar available on society websites.